Amino acids LEEKKGNYVVTDHC were used as the immunogen for the recombinant EGFRvIII antibody. This is the predicted sequence of the exon 2-7 delete fusion region.
EGFR is type I receptor tyrosine kinase with sequence homology to erbB-1, -2, -3 -4 or HER-1, -2, -3 -4. It binds to Epidermal Growth Factor (EGF), Transforming Growth Factor-a (TGF-a), Heparin-binding EGF (HB-EGF), amphiregulin, betacellulin and epiregulin. EGFR is overexpressed in tumors of breast, brain, bladder, lung, gastric, head & neck, esophagus, cervix, vulva, ovary, and endometrium. It is predominantly present in squamous cell carcinomas.
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Antibody Type:
Primary Antibody
Application Dilute:
Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT,Prediluted IHC only format : incubate for 30 min at RT (1)
Application Notes:
Titering of the recombinant EGFRvIII antibody may be required for optimal performance.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* VAT and and shipping costs not included. Errors and price changes excepted
